These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 22040002

  • 1. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
    [Abstract] [Full Text] [Related]

  • 3. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 4. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 5. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB, Xie J, Han Y, Qiu ZF, Li YL, Song XJ, Yu W, Li TS.
    Zhonghua Yi Xue Za Zhi; 2012 May 08; 92(17):1155-8. PubMed ID: 22883000
    [Abstract] [Full Text] [Related]

  • 6. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    J Clin Endocrinol Metab; 2007 Apr 08; 92(4):1283-8. PubMed ID: 17227801
    [Abstract] [Full Text] [Related]

  • 7. Stable bone density in HAART-treated individuals with HIV: a meta-analysis.
    Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR.
    J Clin Endocrinol Metab; 2011 Sep 08; 96(9):2721-31. PubMed ID: 21715534
    [Abstract] [Full Text] [Related]

  • 8. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Mannazzu M, Falchi A, Sanna D, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2009 Jun 08; 53(3):290-301. PubMed ID: 18596668
    [Abstract] [Full Text] [Related]

  • 9. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2004 Mar 08; 48(1):39-48. PubMed ID: 15195003
    [Abstract] [Full Text] [Related]

  • 10. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP, Yu XB, Luo L, Han Y, Qiu ZF, Zuo LY, Li YL, Yu W, Li TS.
    Zhonghua Nei Ke Za Zhi; 2010 Aug 08; 49(8):649-52. PubMed ID: 20979781
    [Abstract] [Full Text] [Related]

  • 11. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
    Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J.
    HIV Med; 2011 Mar 08; 12(3):157-65. PubMed ID: 20722752
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett A.
    HIV Med; 2007 Jul 08; 8(5):280-7. PubMed ID: 17561873
    [Abstract] [Full Text] [Related]

  • 13. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2006 Aug 08; 65(2):191-7. PubMed ID: 16886959
    [Abstract] [Full Text] [Related]

  • 14. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G, Spanu A, Solinas P, Babudieri S, Calia GM, Lovigu C, Mannazzu M, Nuvoli S, Piras B, Bagella P, Mura MS, Madeddu G.
    Eur Rev Med Pharmacol Sci; 2015 Dec 08; 19(23):4576-89. PubMed ID: 26698255
    [Abstract] [Full Text] [Related]

  • 15. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J.
    J Clin Endocrinol Metab; 2004 Mar 08; 89(3):1200-6. PubMed ID: 15001610
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study.
    Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, Podda M, Battezzati PM.
    J Clin Gastroenterol; 2008 Mar 08; 42(3):306-11. PubMed ID: 18223492
    [Abstract] [Full Text] [Related]

  • 19. Bone mineral density changes in women with systemic lupus erythematosus.
    Boyanov M, Robeva R, Popivanov P.
    Clin Rheumatol; 2003 Oct 08; 22(4-5):318-23. PubMed ID: 14579164
    [Abstract] [Full Text] [Related]

  • 20. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.
    HIV Med; 2006 Jan 08; 7(1):38-45. PubMed ID: 16313291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.